Personal information

No personal information available

Activities

Employment (8)

Symberix, Inc.: Durham, North Carolina, US

2013 to present | President and CEO
Employment
Source: Self-asserted source
Ward Peterson

Ward Peterson Consulting, LLC: Morrisville, North Carolina, US

2011 to present | Owner
Employment
Source: Self-asserted source
Ward Peterson

QOL Medical: Vero Beach, Florida, US

2019 to 2021 | Head of Organization Development and Clinical Strategy
Employment
Source: Self-asserted source
Ward Peterson

Regeneron (United States): Tarrytown, New York, US

1999-08-01 to 2020-10-01 | Scientist (Neural and Endocrine Biology)
Employment
Source: Self-asserted source
Ward Peterson

Graybug Vision (United States): Baltimore, Maryland, US

2014-09-01 to 2017-09-01 | Consultant (Senior Vice President
Employment
Source: Self-asserted source
Ward Peterson

Croma Pharma (Austria): Leobendorf, AT

2012 to 2015 | Consultant (Chief Scientific Officer
Employment
Source: Self-asserted source
Ward Peterson

Inspire Pharmaceuticals, Inc.: Durham, North Carolina, US

1999 to 2011 | Senior Vice President (Scientific Affairs and Strategic Interventions)
Employment
Source: Self-asserted source
Ward Peterson

Hawaii Preparatory Academy: Kamuela, Hawaii, US

1986 to 1989 | High School Math and Physics Instructor
Employment
Source: Self-asserted source
Ward Peterson

Education and qualifications (3)

University of California: Berkeley and San Francisco, CA, US

1995-09 to 1998-07 | Postdoc (Vision Science)
Education
Source: Self-asserted source
Ward Peterson

University of California Berkeley: Berkeley, CA, US

1990-09 to 1995-06 | Ph.D. (Biophysics)
Education
Source: Self-asserted source
Ward Peterson

Pomona College: Claremont, CA, US

1982-09 to 1986-05 | B.A. (Physics)
Education
Source: Self-asserted source
Ward Peterson

Professional activities (13)

American Association for the Advancement of Science: Washington, D.C., US

1996 to present | Member
Membership
Source: Self-asserted source
Ward Peterson

Association for Research in Vision and Ophthalmology: Rockville, Maryland, US

1992 to 2018 | Member
Membership
Source: Self-asserted source
Ward Peterson

North Carolina Biotechnology Center: Durham, North Carolina, US

2009 to 2010 | Biotechnology Review Grant Committee
Membership
Source: Self-asserted source
Ward Peterson

Portfolio Management Institute: na, US

2007 to 2010 | Member
Membership
Source: Self-asserted source
Ward Peterson

Contemporary Science Center: Durham, NC, US

2006 to 2010 | Board Member
Membership
Source: Self-asserted source
Ward Peterson

North Carolina Association for Biomedical Research: Raleigh, North Carolina, US

2005 to 2010 | Board Member
Membership
Source: Self-asserted source
Ward Peterson

United States Patent and Trademark Office: Alexandria, Virginia, US

1995 to 1998 | Patent Agent
Service
Source: Self-asserted source
Ward Peterson

National Institutes of Health: Bethesda, MD, US

1996 | NRSA Postdoctoral Fellowship
Distinction
Source: Self-asserted source
Ward Peterson

Fight for Sight: New York, NY, US

1996 | Prevent Blindness America - Fight for Sight Research Award
Distinction
Source: Self-asserted source
Ward Peterson

ARVO Foundation for Eye Research: Md., Md., US

1994 | Association for Research in Vision and Ophthalmology Travel Award
Distinction
Source: Self-asserted source
Ward Peterson

Esther A. & Joseph Klingenstein Fund: New York, New York, US

1988 | Joseph Klingenstein Summer Teaching Fellowship Award
Distinction
Source: Self-asserted source
Ward Peterson

Pomona College: Claremont, CA, US

1986 | Richard P Edmund Undergraduate Prize in Physics (Physics)
Distinction
Source: Self-asserted source
Ward Peterson

Achievement Rewards for College Scientists Foundation: Artesia, California, US

1985 | Achievement Rewards for College Scientists
Distinction
Source: Self-asserted source
Ward Peterson

Funding (6)

Small molecule drugs targeting gut dysbiosis to manage inflammatory bowel disease

2022-06 to 2023-03 | Grant
National Institutes of Health (Bethesda, MD, US)
GRANT_NUMBER:

1R43DK131674-01A1

Source: Self-asserted source
Ward Peterson

Selection and preclinical development of a bacteria-targeting, non-antibiotic lead candidate to improve cancer chemotherapy outcomes

2018-08-20 to 2021-07-31 | Grant
National Cancer Institute (Bethesda, US)
GRANT_NUMBER: R44CA233157
Source: Self-asserted source
Ward Peterson via DimensionsWizard

Qualifying a Novel Microbiome-targeting Compound as an Investigational New Drug (IND) Candidate to Improve Chemotherapy Outcomes

2017-12-08 to present | Grant
North Carolina Biotechnology Center (Durham, US)
GRANT_NUMBER: NC62a6e1c
Source: Self-asserted source
Ward Peterson via DimensionsWizard

Microbiome Targeted Drugs to Improve NSAID Outcomes

2015-09-17 to 2016-08-28 | Grant
National Institute of Diabetes and Digestive and Kidney Diseases (Bethesda, US)
GRANT_NUMBER: R43DK108379
Source: Self-asserted source
Ward Peterson via DimensionsWizard

Improving chemotherapy outcomes with proprietary molecules targeting the human mi

2014-08-06 to 2016-01-31 | Grant
National Cancer Institute (Bethesda, US)
GRANT_NUMBER: R43CA180270
Source: Self-asserted source
Ward Peterson via DimensionsWizard

GENE THERAPY FOR RETINAL DEGENERATIONS TARGETING RPE

1996-03-30 to 1998-01-01 | Grant
National Eye Institute (Bethesda, US)
GRANT_NUMBER: F32EY006780
Source: Self-asserted source
Ward Peterson via DimensionsWizard

Works (15)

Safety and effectiveness of hyaluronic acid dermal filler in correction of moderate-to-severe nasolabial folds in Chinese subjects.

Clinical, cosmetic and investigational dermatology
2019-01-14 | Journal article
Contributors: Dai X; Li L; Peterson W; Renate Baumgartner; Huang J; Baer-Zwick A; Hoeller S; Ivezic-Schoenfeld Z; Prinz M
Source: Self-asserted source
Ward Peterson

Phenotypic characterization of P23H and S334ter rhodopsin transgenic rat models of inherited retinal degeneration.

Experimental eye research
2017-11-06 | Journal article
Contributors: LaVail MM; Nishikawa S; Steinberg RH; Naash MI; Duncan JL; Trautmann N; Matthes MT; Yasumura D; Lau-Villacorta C; Chen J et al.
Source: Self-asserted source
Ward Peterson

A Controlled, Randomized Double-Blind Study to Evaluate the Safety and Efficacy of Chitosan-N-Acetylcysteine for the Treatment of Dry Eye Syndrome.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
2017-04-25 | Journal article
Contributors: Doreen Schmidl; Werkmeister R; Kaya S; Angelika Unterhuber; Witkowska KJ; Baumgartner R; Höller S; O'Rourke M; Peterson W; Wolter A et al.
Source: Self-asserted source
Ward Peterson

Expression profiling after retinal detachment and reattachment: a possible role for aquaporin-0.

Investigative ophthalmology & visual science
2008-02-01 | Journal article
Contributors: Farjo R; Peterson WM; Naash MI
Source: Self-asserted source
Ward Peterson

Effect of 5-MCA-NAT, a putative melatonin MT3 receptor agonist, on intraocular pressure in glaucomatous monkey eyes.

Journal of glaucoma
2004-10-01 | Journal article
Contributors: Serle JB; Wang RF; Peterson WM; Plourde R; Yerxa BR
Source: Self-asserted source
Ward Peterson

Effect of nucleotide P2Y2 receptor agonists on outward active transport of fluorescein across normal blood-retina barrier in rabbit.

Experimental eye research
2004-01-01 | Journal article
Contributors: Takahashi J; Hikichi T; Mori F; Kawahara A; Yoshida A; Peterson WM
Source: Self-asserted source
Ward Peterson

P2Y(2) receptor agonist INS37217 enhances functional recovery after detachment caused by subretinal injection in normal and rds mice.

Investigative ophthalmology & visual science
2003-10-01 | Journal article
Contributors: Nour M; Quiambao AB; Peterson WM; Al-Ubaidi MR; Naash MI
Source: Self-asserted source
Ward Peterson

Localization of ocular P2Y2 receptor gene expression by in situ hybridization.

Experimental eye research
2003-07-01 | Journal article
Contributors: Cowlen MS; Zhang VZ; Warnock L; Moyer CF; Peterson WM; Yerxa BR
Source: Self-asserted source
Ward Peterson

New visions in ophthalmic drug development

Drug Discovery World
2002-12-14 | Journal article
Contributors: Ward Peterson
Source: Self-asserted source
Ward Peterson

Effect of INS37217, a P2Y(2) receptor agonist, on experimental retinal detachment and electroretinogram in adult rabbits.

Investigative ophthalmology & visual science
2002-11-01 | Journal article
Contributors: Meyer CH; Hotta K; Peterson WM; Toth CA; Jaffe GJ
Source: Self-asserted source
Ward Peterson

The P2Y(2) receptor agonist INS37217 stimulates RPE fluid transport in vitro and retinal reattachment in rat.

Investigative ophthalmology & visual science
2002-11-01 | Journal article
Contributors: Maminishkis A; Jalickee S; Blaug SA; Rymer J; Yerxa BR; Peterson WM; Miller SS
Source: Self-asserted source
Ward Peterson

Potency and duration of action of synthetic P2Y2 receptor agonists on Schirmer scores in rabbits.

Advances in experimental medicine and biology
2002-01-01 | Journal article
Contributors: Yerxa BR; Douglass JG; Elena PP; Caillaud T; Amar T; Edick C; Peterson WM
Source: Self-asserted source
Ward Peterson

Ciliary neurotrophic factor and stress stimuli activate the Jak-STAT pathway in retinal neurons and glia.

The Journal of neuroscience : the official journal of the Society for Neuroscience
2000-06-01 | Journal article
Contributors: Peterson WM; Wang Q; Tzekova R; Wiegand SJ
Source: Self-asserted source
Ward Peterson

Extracellular ATP activates calcium signaling, ion, and fluid transport in retinal pigment epithelium.

The Journal of neuroscience : the official journal of the Society for Neuroscience
1997-04-01 | Journal article
PMID: 9065493
Contributors: Peterson WM; Meggyesy C; Yu K; Miller SS
Source: Self-asserted source
Ward Peterson

Identification and functional characterization of a dual GABA/taurine transporter in the bullfrog retinal pigment epithelium.

The Journal of general physiology
1995-12-01 | Journal article
PMID: 8786352
Contributors: Peterson WM; Miller SS
Source: Self-asserted source
Ward Peterson